New shot aims to clear hepatitis b virus in chronic patients
NCT ID NCT07179653
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests an injection called TVAX-008 in 48 adults with chronic hepatitis B who have low levels of the virus. Half receive the drug, half a placebo, to see if it can clear a key virus marker (HBsAg) safely. The study is double-blind and already finished enrolling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TVAX-008 injection
What this could lead to
If successful, this could point toward a way to clear hepatitis B surface antigen, potentially reducing long-term liver damage and the need for ongoing medication.
What could go wrong
This is an early Phase 2 trial with only 48 participants, so results may not apply broadly. The treatment may not achieve HBsAg clearance, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NanFang Hospital
Guangzhou, Guangdong, 20000, China